Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
STAA
HOLDSTAAR Surgical Company · Healthcare · United States · $1.2B · Avg Vol: $19M/d
COMPANY DESCRIPTION
STAAR Surgical Company designs, develops, manufactures, and markets implantable lenses for the eye, primarily its proprietary EVO Visian Implantable Collamer Lens (ICL) for vision correction. The company holds a leadership position in the premium refractive vision correction market due to its unique, patented ICL technology offering superior visual outcomes for suitable patients. It benefits from high barriers to entry in ophthalmology and growing market acceptance of its advanced lens solutions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.4M | 322.4M | 313.9M | 239.4M | -5.6% | 290.4M | 338.2M | 361.5M | 14.7% |
| EPS | 0.81 | 0.44 | -0.41 | -1.62 | -45.7% | -0.38 | — | — | — |
| Shares | 48.2M | 48.8M | 49.3M | 49.4M | +2.5% | 49.8M | — | — | — |
| Debt | 31.0M | 35.8M | 38.7M | 38.4M | 7.3% | 37.3M | — | — | — |
| Equity | 336.1M | 386.0M | 397.3M | 344.2M | 0.8% | — | — | — | — |
| Op CF | 35.7M | 14.6M | 15.7M | -34.2M | -33.6% | -50.2M | — | — | — |
| Inv CF | -156.4M | 74.3M | -59.2M | 46.3M | — | — | — | — | — |
| Fin CF | 8.3M | 7.4M | 5.7M | -4.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STAA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STAA | STAAR Surgical Company(you) | $1.2B | 56 | HOLD |
| BLFS | BioLife Solutions, Inc. | $1.5B | 56 | HOLD |
| AZTA | Azenta, Inc. | $1.3B | 44 | HOLD |
| ATRC | AtriCure, Inc. | $1.8B | 48 | HOLD |
| ANGO | AngioDynamics, Inc. | $562M | 58 | HOLD |
| LMAT | LeMaitre Vascular, Inc. | $2.2B | 75 | BUY |
| XRAY | DENTSPLY SIRONA Inc. | $2.6B | 73 | BUY |
| WRBY | Warby Parker Inc. | $3.0B | 41 | HOLD |
| KMTS | Kestra Medical Technologies, Ltd. | $1.2B | 21 | SELL |
| SMTI | Sanara MedTech Inc. | $234M | 60 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%